Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

1.

Guidelines for quality control of PET/CT scans in a multicenter clinical study.

Hristova I, Boellaard R, Galette P, Shankar LK, Liu Y, Stroobants S, Hoekstra OS, Oyen WJG.

EJNMMI Phys. 2017 Sep 18;4(1):23. doi: 10.1186/s40658-017-0190-7.

PMID:
28924696
2.

Immune Modulation Therapy and Imaging: Workshop Report.

Shields AF, Jacobs P, Sznol M, Graham MM, Germain R, Lum L, Jaffee E, de Vries EGE, Nimmagadda S, Van den Abbeele AD, Leung D, Wu AM, Sharon E, Shankar LK.

J Nucl Med. 2017 Aug 17. pii: jnumed.117.195610. doi: 10.2967/jnumed.117.195610. [Epub ahead of print]

PMID:
28818991
3.

Beyond Correlations, Sensitivities, and Specificities: A Roadmap for Demonstrating Utility of Advanced Imaging in Oncology Treatment and Clinical Trial Design.

Huang EP, Lin FI, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1036-1049. doi: 10.1016/j.acra.2017.03.002. Epub 2017 Apr 26. Review.

PMID:
28456570
4.

Using PET for therapy monitoring in oncological clinical trials: challenges ahead.

Deroose CM, Stroobants S, Liu Y, Shankar LK, Bourguet P.

Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):32-40. doi: 10.1007/s00259-017-3689-1. Epub 2017 Apr 27.

PMID:
28451825
5.

Beyond Correlations, Sensitivities, and Specificities: Case Examples of the Evaluation of Advanced Imaging in Oncology Clinical Trials and Cancer Treatment.

Lin FI, Huang EP, Shankar LK.

Acad Radiol. 2017 Aug;24(8):1027-1035. doi: 10.1016/j.acra.2016.11.024. Epub 2017 Apr 11. Review.

PMID:
28410912
6.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EG; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review.

PMID:
28271869
7.

Qualification of National Cancer Institute-Designated Cancer Centers for Quantitative PET/CT Imaging in Clinical Trials.

Scheuermann JS, Reddin JS, Opanowski A, Kinahan PE, Siegel BA, Shankar LK, Karp JS.

J Nucl Med. 2017 Jul;58(7):1065-1071. doi: 10.2967/jnumed.116.186759. Epub 2017 Mar 2. Review.

PMID:
28254874
8.

A comparison of FLT to FDG PET/CT in the early assessment of chemotherapy response in stages IB-IIIA resectable NSCLC.

Crandall JP, Tahari AK, Juergens RA, Brahmer JR, Rudin CM, Esposito G, Subramaniam DS, Knopp MV, Hall NC, Gajwani P, Leal JP, Lodge MA, O JH, Gabrielson EW, Shankar LK, Wahl RL.

EJNMMI Res. 2017 Dec;7(1):8. doi: 10.1186/s13550-017-0258-3. Epub 2017 Jan 19.

9.

Clinical Translation of the National Institutes of Health's Investments in Nanodrug Products and Devices.

Henderson LA, Shankar LK.

AAPS J. 2017 Mar;19(2):343-359. doi: 10.1208/s12248-016-9995-x. Epub 2016 Dec 19.

PMID:
27995455
10.

Imaging biomarker roadmap for cancer studies.

O'Connor JP, Aboagye EO, Adams JE, Aerts HJ, Barrington SF, Beer AJ, Boellaard R, Bohndiek SE, Brady M, Brown G, Buckley DL, Chenevert TL, Clarke LP, Collette S, Cook GJ, deSouza NM, Dickson JC, Dive C, Evelhoch JL, Faivre-Finn C, Gallagher FA, Gilbert FJ, Gillies RJ, Goh V, Griffiths JR, Groves AM, Halligan S, Harris AL, Hawkes DJ, Hoekstra OS, Huang EP, Hutton BF, Jackson EF, Jayson GC, Jones A, Koh DM, Lacombe D, Lambin P, Lassau N, Leach MO, Lee TY, Leen EL, Lewis JS, Liu Y, Lythgoe MF, Manoharan P, Maxwell RJ, Miles KA, Morgan B, Morris S, Ng T, Padhani AR, Parker GJ, Partridge M, Pathak AP, Peet AC, Punwani S, Reynolds AR, Robinson SP, Shankar LK, Sharma RA, Soloviev D, Stroobants S, Sullivan DC, Taylor SA, Tofts PS, Tozer GM, van Herk M, Walker-Samuel S, Wason J, Williams KJ, Workman P, Yankeelov TE, Brindle KM, McShane LM, Jackson A, Waterton JC.

Nat Rev Clin Oncol. 2017 Mar;14(3):169-186. doi: 10.1038/nrclinonc.2016.162. Epub 2016 Oct 11. Review.

11.

Imaging and Data Acquisition in Clinical Trials for Radiation Therapy.

FitzGerald TJ, Bishop-Jodoin M, Followill DS, Galvin J, Knopp MV, Michalski JM, Rosen MA, Bradley JD, Shankar LK, Laurie F, Cicchetti MG, Moni J, Coleman CN, Deye JA, Capala J, Vikram B.

Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):404-11. doi: 10.1016/j.ijrobp.2015.10.028. Epub 2015 Oct 24. Review.

12.

A risk management approach for imaging biomarker-driven clinical trials in oncology.

Liu Y, deSouza NM, Shankar LK, Kauczor HU, Trattnig S, Collette S, Chiti A.

Lancet Oncol. 2015 Dec;16(16):e622-8. doi: 10.1016/S1470-2045(15)00164-3. Review.

PMID:
26678215
13.

Are we ready for the 10% solution?

Chen HX, Rubinstein LV, Shankar LK, Abrams JS.

Oncologist. 2014 May;19(5):439-40. doi: 10.1634/theoncologist.2014-0126. Epub 2014 Apr 22. No abstract available.

14.

A phase 2 study of 16α-[18F]-fluoro-17β-estradiol positron emission tomography (FES-PET) as a marker of hormone sensitivity in metastatic breast cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2014 Jun;16(3):431-40. doi: 10.1007/s11307-013-0699-7. Epub 2013 Oct 30.

15.

The clinical evaluation of novel imaging methods for cancer management.

Shankar LK.

Nat Rev Clin Oncol. 2012 Dec;9(12):738-44. doi: 10.1038/nrclinonc.2012.186. Epub 2012 Nov 13. Review.

PMID:
23149888
16.

Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis.

de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA, Hoekstra OS.

J Nucl Med. 2012 May;53(5):701-8. doi: 10.2967/jnumed.111.095299. Epub 2012 Apr 10.

17.

Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Dancey JE, Dobbin KK, Groshen S, Jessup JM, Hruszkewycz AH, Koehler M, Parchment R, Ratain MJ, Shankar LK, Stadler WM, True LD, Gravell A, Grever MR; Biomarkers Task Force of the NCI Investigational Drug Steering Committee.

Clin Cancer Res. 2010 Mar 15;16(6):1745-55. doi: 10.1158/1078-0432.CCR-09-2167. Epub 2010 Mar 9.

18.

Challenges in clinical prostate cancer: role of imaging.

Kelloff GJ, Choyke P, Coffey DS; Prostate Cancer Imaging Working Group.

AJR Am J Roentgenol. 2009 Jun;192(6):1455-70. doi: 10.2214/AJR.09.2579.

19.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA.

Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55. doi: 10.1007/s11307-009-0215-2. Epub 2009 Mar 27.

20.

Considerations for the use of imaging tools for phase II treatment trials in oncology.

Shankar LK, Van den Abbeele A, Yap J, Benjamin R, Scheutze S, Fitzgerald TJ.

Clin Cancer Res. 2009 Mar 15;15(6):1891-7. doi: 10.1158/1078-0432.CCR-08-2030. Epub 2009 Mar 10. Review.

Supplemental Content

Loading ...
Support Center